Gut Microbiome and p-Inulin in CKD - TarGut CKD Study

The overarching hypothesis motivating this exploratory study of variability is that treatment with oligofructose-enriched inulin (p-inulin) will alter the composition and/or function of the gut microbiome, and thereby reduce the generation of gut-derived uremic toxins, improve gut barrier function and attenuate systemic inflammation in CKD patients. In order to design a future clinical trial the following parameters from CKD subjects are needed: 1. Intra-patient variability in the composition and function of the gut microbiome 2. Inter-patient variability in the composition and function of the gut microbiome 3. Impact of p-inulin on the composition and function of the gut microbiome 4. Tolerability of p-inulin administration 5. Feasibility of collecting stool samples in this patient population